Free Trial

PetIQ Q1 2023 Earnings Report

PetIQ EPS Results

Actual EPS
$0.38
Consensus EPS
$0.25
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

PetIQ Revenue Results

Actual Revenue
$290.47 million
Expected Revenue
$278.69 million
Beat/Miss
Beat by +$11.78 million
YoY Revenue Growth
N/A

PetIQ Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Register for the FREE Workshop Now & get $10 in Bitcoin

PetIQ Earnings Headlines

PetIQ Acquired by Bansk Group, Delisted from Nasdaq
PetIQ announces completion of acquisition by Bansk Group
2025 AI Stock Picks: 2 Hidden Gems Under $10/Share
The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.
PetIQ Merges with Bansk Group in $1.5B Deal
See More PetIQ Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PetIQ? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PetIQ and other key companies, straight to your email.

About PetIQ

PetIQ (NASDAQ:PETQ) operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats. It also provides OTC medications and supplies primarily within the flea and tick control, dog dewormers, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dog and cat treats, oral health solutions, stain and odor treatments, and pet nutritional supplements under the PetArmor®, Rocco & Roxie®, VetIQ®, Minties® and Sentry® brands. It provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PurLuv, Rocco & Roxie, Minties, Heart Shield Plus, and TruProfen brand names. In addition, the company operates veterinarian service platform through community clinics, pop-up locations, wellness centers, and permanent locations that offer cost effective and convenient veterinary wellness services, including diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene, and wellness checks; and provides veterinary care services. It operates through veterinarian, retail, and e-commerce channels. PetIQ, Inc. was founded in 2010 and is headquartered in Eagle, Idaho.

View PetIQ Profile

More Earnings Resources from MarketBeat

Upcoming Earnings